Research Article
Predictors of Improvement in Quality of Life When Treating Hypothyroidism

Bjarke Borregaard Medici,1,2 Jeppe Lerche la Cour,1 Filip Krag Knop,2,3,4 Martin Krakauer,5 Luba Freja Michaelsson,1 Jens Faber,1,3 Torquil Watt,1 and Birte Nygaard1

1Department of Medicine, Herlev and Gentofte Hospital, University of Copenhagen, Herlev Ringvej 75, Herlev 2730, Denmark
2Center for Clinical Metabolic Research, University of Copenhagen, Gentofte Hospital, Kildegårdsvæj 28, Opgang 7, 3. Sal, Hellerup 2900, Denmark
3Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Nørre Allé 20, Copenhagen 2200, Denmark
4Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
5Department of Clinical Physiology and Nuclear Medicine, Herlev and Gentofte Hospital, University of Copenhagen, Gentofte Hospitalvej 2, 1. Sal, th, Hellerup, Denmark

Correspondence should be addressed to Bjarke Borregaard Medici; bjarkemedici@hotmail.com

Received 5 February 2021; Accepted 5 June 2021; Published 12 June 2021

Academic Editor: Anjali Mishra

Copyright © 2021 Bjarke Borregaard Medici et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Primary hypothyroidism is characterized by reduced quality of life (QoL). Although thyrotropin (TSH) is considered the most sensitive marker for evaluating the severity of hypothyroidism, the burden of symptoms does not correlate with TSH concentrations [4–6]. Levothyroxine treatment improves QoL in patients with hypothyroidism [1, 2]. Thyrotropin (TSH) is considered the most sensitive marker for evaluating the severity of hypothyroidism. Nevertheless, in the clinical setting, the burden of symptoms does not correlate with TSH concentrations [4–6]. Levothyroxine treatment improves QoL in patients with hypothyroidism [1, 2].

1. Introduction

Hypothyroidism is characterized by reduced quality of life (QoL), due to a range of diverse symptoms [1, 2], with tiredness and emotional susceptibility being prominent complaints [3]. Thyrotropin (TSH) is considered the most sensitive marker for evaluating the severity of hypothyroidism. Nevertheless, in the clinical setting, the burden of symptoms does not correlate with TSH concentrations [4–6]. Levothyroxine treatment improves QoL in patients with hypothyroidism [1, 2].
with hypothyroidism, but 5–10% still report symptoms despite adequate levothyroxine (L-T4) dosage [7]. These residual symptoms remain puzzling, though several explanations have been suggested, including insufficient hormone substitution to normalize triiodothyronine (T3) in all tissues, coexistence of other autoimmune conditions, the awareness of being dependent on medicine, and symptoms not originating from thyroid insufficiency [7, 8]. Importantly, overweight is a frequent phenomenon among patients with hypothyroidism and in the general population, and overweight is strongly associated with reduced QoL. The risk of overweight is influenced by many factors, including genetics [9]; nonetheless, daily calorie intake surmounting daily calorie expenditure remains the core problem [10]. Daily calorie expenditure is comprised of dietary-induced thermogenesis (10–15%), physical activity (10–30%), and resting energy expenditure (REE) (60–80%). Therapy with L-T4 significantly increases REE in hypothyroidism [11] due to increased tissue metabolism [12]. Cognitive complaints are common among hypothyroid patients [13], and a connection between cognitive function and QoL may exist, similar to the correlation between cognitive deficits and depression observed in patients with multiple sclerosis [14].

The aim of this study was to investigate changes in clinically relevant predictors (REE, body composition, thyroid function, L-T4 dose, and cognitive function tests) during initiation of L-T4 therapy and their ability to predict improvement in QoL as measured by ThyPRO-39 [15].

2. Methods

2.1. Study Design. This was a prospective clinical cohort study, including newly diagnosed hypothyroid patients, followed during the initial 12 months of L-T4 therapy. Patients were recruited from a university hospital endocrine outpatient clinic, by advertising and through the Copenhagen General Population Study [16]. Inclusion criteria were diagnosis of primary hypothyroidism with TSH above 10 mU/l measured at two consecutive occasions and age of 20–75 years. Exclusion criteria were hypothyroidism due to thyroid surgery or pituitary disease, other diseases that might interfere with thyroid function, subacute thyroiditis, and pregnancy. The study comprised three identical visits. The first visit was intended to be before initiating L-T4 treatment, albeit 1–2 weeks of low dose L-T4 therapy (≤50 μg per day) was accepted for patients with severe symptoms. Following the first visit, the dose was increased with short intervals towards normalization of TSH. Second and third visits were conducted after 6 and 12 months of L-T4 therapy, respectively.

2.2. Outcomes. The primary outcome was a correlation between the increase in REE and QoL measured using the ThyPRO-39 questionnaire. Secondary outcomes encompassed other possible predictors of increase in QoL from therapy: change in body weight, body composition, thyroid parameters, and cognition tests.

2.3. Study Procedures. Before each study visit, QoL was measured by participants completing an online version of ThyPRO-39 [15]. ThyPRO-39 scales range 0–100, with higher levels corresponding to more symptoms or more QoL impairment. The Composite score (summarizing all ThyPRO-39 impairment scales), as well as the Tiredness and Emotional Susceptibility scales, was evaluated [17]. Before each visit, participants were fasting from midnight, avoided exercise the preceding night, and arrived in the morning at the hospital by the least physically active way [18]. Body composition (fat mass (FM) and fat-free mass (FFM)) was determined by dual x-ray absorptiometry, each participant using the same scanner for the entire study (Lunar iDXA; GE Healthcare, Fairfield, CT, USA, or Hologic Discovery scanner, Hologic Inc., USA). Bodyweight was measured on a routinely calibrated scale. On each study visit, blood was drawn for analysis of thyroid function. REE was measured by indirect calorimetry for 12 minutes on a CCM Express calorimeter from MGC diagnostics using a facemask after 20 minutes of resting in the supine position [19, 20]. Since REE is particularly dependent on FFM [21, 22], REE was reported and analyzed as REE/FFM (kcal/day/kg). Similarly, the dose of L-T4 is presented as dose/week/FFM (μg/week/kg) [23]. Cognitive function was tested using California Computerized Assessment Package (CalCAP®; Eric Miller, Palm Springs, CA, USA) testing sequential reaction time (SRT) [24], test 1 (SRT1): respond when two numbers in sequence were identical; test 2 (SRT2): respond when two numbers in sequence were in increasing order. Cognitive function was further tested using Symbol Digit Modalities Test scoring 1–100 with a high number indicating better cognitive function [25].

2.4. Serum Analyses. It includes thyrotropin (reference range 0.35–4.0 mU/l), thyroxine (T4) (reference range 60–140 nmol/l), free T4 (fT4) (reference range 11.5–22.7 pmol/l), total T3 (reference range 1.0–2.6 nmol/l), and thyroid peroxidase antibodies (anti-TPO) (reference range <60 kU/l). Due to changes in routine T4 assays, seven patients had fT4 measured instead of total T4. All tests were done on ADVIA Centaur XP from Siemens (Ballerup, Denmark) on the day of the study visit.

2.5. Calculations and Statistics. Parametric and nonparametric tests were used according to the distribution of data and presented by mean with SD and median with 1st and 3rd quartiles (Q1–Q3), respectively. In linear regression analyses, the ThyPRO-39 Composite Scale was used as the dependent factor to assess the association between predictors and change in QoL. Nonparametric data were analyzed using bootstrapping [26]. Multiple linear regression was used to generate the model with the best ability to predict change in QoL score. Univariate statistics are presented with the unstandardized coefficient (USC) with confidence interval (CI), which is the estimated change in ThyPRO score from visits 1 to 3 when changing one unit of the predicting variable. After excluding variables due to multicollinearity, multiple regression analyses using the forward stepwise
method were conducted, including all suspected predictors. Included variables were changes during the study including REE/FFM, log-TSH, and T3; variables from visit 1 were age, body mass index (BMI), sequential reaction times 1 and 2, Symbol Digit Modalities Test, FFM/FM-ratio, and from visit 3, dose of L-T4 per FFM. All statistics were calculated on IBM SPSS statistics data editor version 22.

3. Results
Seventy-eight hypothyroid patients were screened, and 37 (25 females, mean age 43, SD 13) were included in the study (Figure 1). At visit 2, one patient missed cognitive testing, one patient missed REE-measurement due to technical failure, and four patients did not complete the ThyPRO-39 questionnaire. Data from these patients were only used when comparing visit 1 to visit 3. None of the patients was diagnosed with or treated for depression or other psychiatric diseases during the study.

3.1. TSH and Dosage. At the first study visit, median TSH was 33 mU/l (range 10–332), and 36 patients had elevated TPO antibodies. Twenty-seven patients were overtly hypothyroid (elevated TSH combined with T4 and/or FT4 below 70 mmol/l and 12 pmol/l, resp.) with a median TSH level of 75 mU/l, and ten patients were subclinically hypothyroid (elevated TSH with normal T4 and/or FT4 concentrations) with a median TSH of 14 mU/l. Of the 37 patients included, 26 initiated L-T4 therapy after visit 1 (baseline median TSH 28.4 (Q1–Q3: 12.5–111 mU/l)), whereas 11 patients were treated for 1–2 weeks with L-T4 (25–50 μg/day) before visit 1 (baseline median TSH 77 mU/l (Q1–Q3: 16.7–93)). Between visits 1 and 2, TSH, T4, FT4, and T3 levels all normalized and did not significantly change further (Table 1). At visit 2, the mean dosage of L-T4 was 890 (SD 211) μg/week, and at visit 3 the mean dosage was 944 (SD 231) μg/week, with the latter corresponding to 1.7 μg/kg body mass per day or 2.6 μg/kg FFM per day.

3.2. REE and QoL. As seen in Table 1, the ThyPRO-39 QoL scale improved by median 14 (Q1–Q3: 3–29) during the study (p < 0.001) from visit 1 to visit 3 but did not change significantly between visits 2 and 3 and was not influenced by gender or thyroid status. Both unadjusted REE and REE/FFM increased (p = 0.002 and p = 0.001, resp.), with no difference between gender or degree of hypothyroidism (overt/subclinical). REE/FFM was higher among women than men at all visits (p < 0.001). Improvement in ThyPRO-39 QoL score did neither correlate (univariate regression analysis) to increase in REE/FFM from visits 1 to 2 nor increase in REE/FFM from visits 1 to 3 (USC 0.09, CI: −1.93 to 2.11, p = 0.93).

From the forward stepwise multiple regression analysis, we constructed a model including BMI, L-T4 dose at visit 3, and age. The adjusted R-squared value of the model was 0.43 (p = 0.027). In this model, USC was 2.1 kg/m² for BMI, 15.8 μg/kg FFM/day for dose at visit 3, and −0.5 years for age.

In a multivariate analysis controlling for BMI, age, and L-T4 dose at visit 3, the correlation between the increase in REE/FFM and improvement in ThyPRO-39 remained insignificant (USC −0.77, CI: −2.35 to 0.81, p = 0.33).

3.3. BMI and QoL. Baseline BMI predicted improvement in ThyPRO-39 score from treatment (USC 1.54, CI: 0.59 to 2.49, p = 0.002) (Table 2) and was not correlated to baseline TSH (p = 0.998), T4 (p = 0.39), or T3 (p = 0.73). At visit 1, BMI correlated with ThyPRO-39 score (USC 1.82, CI: 0.64 to 2.99), but not at visit 2 (USC 0.50, CI: −0.51 to 1.51), nor at visit 3 (USC 0.37, CI: −0.41 to 1.14), while BMI decreased by approximately 0.5 kg/m² from baseline (Table 1). Comparing patients with BMI above or below 25 kg/m², QoL was significantly worse in the high BMI group at baseline (p = 0.03), whereas QoL was similar between the two groups at visit 3 (p = 0.36). Thus, the group with high BMI demonstrated a larger improvement in ThyPRO-39 score than the group with normal BMI (25.0 vs. 11.1, p = 0.04). The two groups did not differ regarding weight loss (p = 0.3) or REE/FFM during treatment (p = 0.3). Baseline ThyPRO-39 score significantly predicted improvement in ThyPRO-39 score from visits 1 to 3 (USC 0.7, CI: 0.53 to 0.86, p < 0.001).

4. Discussion
In this study, we looked for clinically relevant predictors of improvement in QoL, as measured by the ThyPRO-39 Composite scale, during initiation of L-T4 treatment in patients with primary hypothyroidism. We hypothesized that changes in REE would be a sensitive predictor for improving QoL during treatment. However, although REE increased, no association with ThyPRO-39 was found. In contrast, BMI at baseline was a strong predictor of improved QoL during treatment, even though patients with high BMI did not lose more weight during treatment compared to patients with BMI below 25 kg/m². Thus, the higher the pretreatment BMI, the better the outcome regarding QoL during L-T4 treatment for hypothyroidism.

Thyrotropin is recognized as the primary measure for evaluating the need for initiating or adjusting L-T4 therapy [26, 27]. However, the ability of TSH to reflect symptoms varies; one study demonstrated a correlation between the number of symptoms and TSH [4], while other studies did not [6, 8]. REE is the product of consumed oxygen and exhaled carbon dioxide [28] and hence directly reflects an integral part of energy metabolism. Considering that REE increases from L-T4 therapy [11], we hypothesized that REE reflects changes in QoL from L-T4 therapy better than TSH, and we, therefore, investigated REE/FFM as a predictor of changes in QoL scores. Our data, which are the first to evaluate this, do not support our hypothesis. Although patients had a significant and clinically relevant increase in
Table 2: Predictors of improvement in QoL (ThyPRO-39) from visit 1 to visit 3.

| Predictor | Unstandardized coefficient with CI | p value |
|-----------|------------------------------------|---------|
| REE       | Change in REE/FFM from visits 1 to 3 (kcal/day per kg) | 0.09 (−1.93 to 2.11) | 0.93 |
| Thyroid function | TSH at visit 1* (mU/l) | 0.052 (−0.04 to 0.20) | 0.37 |
| | Change in TSH from visits 1 to 3* | 0.053 (−0.04 to 0.20) | 0.33 |
| | Increase in total T3 from visits 1 to 3 (mmol/l) | 10.39 (−3.67 to 24.46) | 0.14 |
| | T3 at visit 3 (mmol/l) | 10.37 (−15.90 to 36.70) | 0.43 |
| Dosage | Dosage L-T4 at visit 3 (μg/week) | 0.034 (0.01 to 0.06) | 0.02 |
| | Dosage L-T4/FFM at visit 3 (μg/kg FFM per week) | 1.05 (−0.81 to 2.91) | 0.26 |
| Age | Age (yr) | −0.38 (−0.90 to 0.13) | 0.14 |
| Body composition | BMI at visit 1 (kg/m²) | 1.54 (0.59 to 2.49) | 0.002 |
| | FFM/FFM-ratio at visit 1 | −6.45 (−12.20 to −0.69) | 0.03 |
| | Weight loss between visits 1 and 3 (kg) | 0.33 (−1.21 to 1.27) | 0.96 |
| Cognitive function tests at visit 1 | Sequential reaction time 1* (ms) | −0.03 (−0.10 to 0.04) | 0.38 |
| | Sequential reaction time 2* (ms) | 0.00 (−0.06 to 0.06) | 0.95 |
| | SDMT score at visit 1 | 0.39 (−0.37 to 1.15) | 0.3 |

* Calculated with bootstrap. CI: confidence interval. The unstandardized coefficient is the estimated change in ThyPRO-39 composite score from visits 1 to 3 when changing one unit of the predicting variable. REE, resting energy expenditure; FFM, fat-free mass; FM, fat mass; kcal, 1000 calories; TSH, thyrotropin; T3, triiodothyronine; L-T4, levothyroxine; BMI, body mass index; SDMT, symbol digit modalities test.
QoL score and a significant increase in REE/FFM, the linear regression for REE/FFM as a predictor of QoL improvement was insignificant when controlling for BMI, age, and L-T4 dose/FFM at visit 3. Although this study is of limited size, the range of the confidence interval is widely around zero indicating that the negative result was not due to a type 2 error. No previous study has evaluated a correlation between REE and QoL in hypothyroid patients. As the study has a limited size, we may have overlooked a minor clinical insignificant correlation.

There is a known negative correlation between BMI and QoL in general [29, 30]. Similarly, in the present study, ThyPRO-39 score at baseline was worse among overweight subjects. In our study, we found a correlation between baseline BMI and improvement in ThyPRO-39 during L-T4 treatment, indicating that the higher the BMI is, the more the benefit from L-T4 therapy might be expected. One might argue that baseline ThyPRO-39 should have been included in the multivariate analysis model, and by doing this, baseline ThyPRO-39 independently predicted a reduction in QoL. Further, both age and BMI became insignificant predictors, while L-T4 dose per FFM remained significant \((p = 0.04)\). However, we chose not to include baseline ThyPRO-39 in the model, since this was not a placebo-controlled randomized trial. Thus, given the design of our study, we cannot estimate the placebo-effect nor the effect from regression towards the mean in QoL, and therefore, we did not include baseline ThyPRO-39 as a predictor of change in ThyPRO-39.

Overweight hypothyroid patients may experience more benefit from L-T4 therapy, due to a lower baseline QoL, which is similar to a meta-analysis demonstrating that patients with more severe depression seem to have greater benefit from both antidepressant and placebo therapy [31].

In other words, patients with the worst symptoms will experience a larger improvement from therapy. This additional benefit may be described as regression towards the mean, comparable to a placebo effect, and we would expect it to dissipate over time.

Studies have demonstrated that the weight loss produced by L-T4 therapy in hypothyroidism primarily originates from loss of FFM [11, 32], and weight gain has even been reported after the initial weight loss [33]. Theoretically, to maintain body weight and composition against an increase in REE of 81 kcal/day (energy intake should increase corresponding to 7.6 kg sugar or 70.4 l regular cola per year), we, therefore, suggest that L-T4 therapy may require a simultaneous diet for a permanent weight loss to occur.

Dosage of L-T4 per FFM was included in the multiple regression model but did not significantly predict change in QoL score in the univariate regression analysis. A higher dosage of L-T4 would, in most cases, lead to a lower TSH in patients. However, TSH and T3 levels were not correlated to change in QoL. These findings are similar to observations from a double-blind crossover trial comparing three different TSH targets, in patients with hypothyroidism. The L-T4 dosage preferred by patients was not determined by TSH, but seemingly by the patients’ perception of high L-T4 dose [34].

Cognitive tests did not predict changes in QoL, and only the Symbol Digit Modalities Test score increased significantly between visits 1 and 3. The modest increase in test score was probably due to learning from repeated attempts and not due to increased cognitive performance [25].

A strength of this study is the inclusion of both female and male patients with a TSH > 10 mU/l, all treated according to guidelines. Another strength is the long follow-up that takes into consideration seasonal changes in behavior and mood. Limitations to this study are the limited size, and the open-label design without a control group due to ethical reasons. Further, we did not include T’4 or fT4 in regression analyses, as two different assays had been utilized, which is a limitation.

5. Conclusion

During the initiation of L-T4 therapy, improvement in QoL as measured on the ThyPRO-39 scale was not associated with changes in REE. In contrast, a higher baseline BMI indicated a better outcome with regard to QoL during L-T4 treatment, whereas the change in BMI during treatment did not seem to affect QoL.

Data Availability

The data are stored on a secured drive at Herlev Hospital, Denmark. No public data have been utilized.

Ethical Approval

The study was approved by the Research Ethics Committee of the Capital Region of Denmark (reg. no. H-1-2014-133) and conducted in accordance with the latest revision of the Declaration of Helsinki.

Consent

All the subjects have given their written informed consent before participation in this study.

Disclosure

This study received economic support from external funds. The funders had no influence on any part of the planning, execution, or conclusions of this study. This article has been presented in an abstract form at the 42nd Annual Meeting of the European Thyroid Association and at the Danish Endocrine Society’s annual meeting, 2018.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Acknowledgments

The authors wish to thank Agnes and Knut Mørks Foundation, Johannes Foghs Foundation, Hede-Nielsens Foundation, the Department of Internal Medicine at Herlev Hospital, and The Research Council at Herlev Hospital for
financial support. Further, they wish to thank the Copenhagen General Population Study for recruitment support.

References

[1] T. Watt, P. Cramon, L. Hegedüs et al., “The thyroid-related quality of life measure ThyPRO has good responsiveness and ability to detect relevant treatment effects,” The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 10, pp. 3708–3717, 2014.

[2] G. P. Bianchi, V. Zacccheroni, E. Solaroli et al., “Health-related quality of life in patients with thyroid disorders,” Quality of Life Research, vol. 13, no. 1, pp. 45–54, 2004.

[3] K. H. Winther, P. Cramon, T. Watt et al., “Disease-specific as well as generic quality of life is widely impacted in autoimmune hypothyroidism and improves during the first six months of levothyroxine therapy,” PLoS One, vol. 11, no. 6, Article ID e0156925, 2016.

[4] G. J. Canaris, J. F. Steiner, and E. C. Ridgway, “Do traditional symptoms of hypothyroidism correlate with biochemical disease?” Journal of General Internal Medicine, vol. 12, no. 9, pp. 544–550, 1997.

[5] E. I. Klaver, H. C. M. Van Loon, R. Stienstra et al., “The thyroid hormone status and health-related quality of life in the lifeLines cohort study,” Thyroid, vol. 23, no. 9, pp. 1066–1073, 2013.

[6] T. Watt, T. Watt, L. Hegedüs et al., “Is thyroid autoimmunity per se a determinant of quality of life in patients with autoimmune hypothyroidism?” European Thyroid Journal, vol. 1, no. 3, pp. 186–192, 2012.

[7] W. M. Wiersinga, Nature Reviews Endocrinology, vol. 10, no. 3, pp. 164–174, 2014.

[8] J. P. W. De Castro, T. L. Fonseca, C. B. Ueta et al., “Differences in hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to thyroxine,” Journal of Clinical Investigation, vol. 125, no. 2, pp. 769–781, 2015.

[9] C. Jou, “The biology and genetics of obesity—a century of inquiries,” The New England Journal of Medicine, vol. 370, no. 20, pp. 1874–1877, 2014.

[10] B. A. Swinburn, I. Caterson, J. C. Seidell, and W. P. James, “Diet, nutrition and the prevention of excess weight gain and obesity,” Public Health Nutrition, vol. 7, no. 1a, pp. 123–146, 2004.

[11] J. Karmisholt, S. Andersen, and P. Laurberg, “Weight loss after therapy of hypothyroidism is mainly caused by excretion of excess body water associated with myxoedema,” The Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 1, pp. 99–103, 2015.

[12] J. E. Silva, “Thyroid hormone control of thermogenesis and energy balance,” Thyroid, vol. 5, no. 6, pp. 481–492, 1995.

[13] M. H. Samuels, “Psychiatric and cognitive manifestations of hypothyroidism,” Current Opinion in Endocrinology & Diabetes and Obesity, vol. 21, no. 5, pp. 377–383, 2014.

[14] L. Samartzis, E. Gavala, Y. Zoukos, A. Aspiotis, and T. Thomaides, “Perceived cognitive decline in multiple sclerosis impacts quality of life independently of depression,” Rehabilitation Research and Practice, vol. 2014, Article ID 128751, 6 pages, 2014.

[15] T. Watt, L. Hegedüs, M. Groenvold et al., “Validation and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO,” European Journal of Endocrinology, vol. 162, no. 1, pp. 161–167, 2010.

[16] A. Fuchs, M. R. Mejdahl, J. T. Kihl et al., “Normal values of left ventricular mass and cardiac chamber volumes assessed by 320-detector computed tomography angiography in the Copenhagen general population study,” European Heart Journal—Cardiovascular Imaging, vol. 17, no. 9, pp. 1009–1017, 2016.

[17] T. Watt, J. B. Björner, M. Groenvold et al., “Development of a short version of the thyroid-related patient-reported outcome ThyPRO,” Thyroid, vol. 25, no. 10, pp. 1069–1079, 2015.

[18] M. A. Stokes and G. L. Hill, “A single, accurate measurement of resting metabolic expenditure,” Journal of Parenteral and Enteral Nutrition, vol. 15, no. 3, pp. 281–287, 1991.

[19] J. H. Borges, R. D. Langer, V. X. Cirolini, M. A. Páscoa, G. Guerra-Júnior, and E. M. Gonçalves, “Minimum time to achieve the steady state and optimum abbreviated period to estimate the resting energy expenditure by indirect calorimetry in healthy young adults,” Nutrition in Clinical Practice, vol. 31, no. 3, pp. 349–354, 2016.

[20] B. Snell, S. Fullmer, D. L. Eggett, and D. L. Eggett, “Reading and listening to music increase resting energy expenditure during an indirect calorimetry test,” Journal of the Academy of Nutrition and Dietetics, vol. 114, no. 12, pp. 1939–1942, 2014.

[21] C. N. Kistorp, S. Toubro, A. Astrup, and O. L. E. Svendsen, “Measurements of body composition by dual-energy x-ray absorptiometry improve,” Annals of New York Academy of Sciences, vol. 904, pp. 79–84, 2000.

[22] M. J. Müller, D. Kutzner, and M. Heller, “Metabolically active components of fat-free mass and resting energy expenditure in humans: recent lessons,” no. 3, pp. 113–122, 2002.

[23] F. Santini, A. Pinchera, A. Marsili et al., “Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases,” The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 1, pp. 124–127, 2005.

[24] Q. T. Vo, C. Cox, X. Li et al., “Neuropsychological test performance before and after HIV-1 seroconversion: the multicenter AIDS cohort study,” Journal of Neurovirology, vol. 19, no. 1, pp. 24–31, 2013.

[25] S. Morrow, P. O’Connor, C. Polman et al., “Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks,” Multiple Sclerosis Journal, vol. 16, no. 11, pp. 1385–1392, 2010.

[26] J. Jonklaas, A. C. Bianco, A. J. Bauer et al., “Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replace-” Thyroid, vol. 24, no. 12, pp. 1670–1731, 2014.

[27] S. H. S. Pearce, G. Brabant, L. H. Duntas et al., “2013 ETA guideline: management of subclinical hypothyroidism,” European Thyroid Journal, vol. 2, no. 4, pp. 215–228, 2013.

[28] J. B. Weir, “New methods for calculating metabolic rate with special reference to protein metabolism,” The Journal of Physiology, vol. 109, no. 1-2, pp. 1–9, 1949.

[29] N. Kelderman-Bolk, T. J. Visser, J. T. Tijssen, and A. Berghout, “Quality of life in patients with primary hypothyroidism related to BMI,” European Journal of Endocrinology, vol. 173, no. 4, pp. 507–515, 2015.

[30] R. Schwarz and A. Hinz, “Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population,” European Journal of Cancer, vol. 37, pp. 1345–1351, 2001.

[31] J. C. Fournier, R. J. DeRubeis, S. D. Hollon et al., “Antidepressant drug effects and depression severity,” JAMA—Journal of the American Medical Association, vol. 303, no. 1, pp. 47–53, 2010.

[32] A. Sánchez, H. Carretto, M. R. Ulla, and R. Capozza, “Body composition of patients with primary hypothyroidism
evaluated by dual-energy x-ray absorptiometry and its changes after treatment with levo-thyroxine,” *The Endocrinologist*, vol. 14, no. 6, pp. 321–327, 2004.

[33] B. J. Hoogwerf and F. Q. Nuttall, “Long-term weight regulation in treated hyperthyroid and hypothyroid subjects,” *The American Journal of Medicine*, vol. 76, no. 6, pp. 963–970, 1984.

[34] M. H. Samuels, I. Kolobova, M. Niederhausen, J. S. Janowsky, and K. G. Schuff, “Effects of altering levothyroxine (L-T4) doses on quality of life, mood, and cognition in L-T4 treated subjects,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 103, no. 5, pp. 1997–2008, 2018.